|Table of Contents|

Analysis of the efficacy of icotinib in the treatment of advanced lung adenocarcinoma with different mutation types of EGFR

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 06
Page:
961-964
Research Field:
Publishing date:

Info

Title:
Analysis of the efficacy of icotinib in the treatment of advanced lung adenocarcinoma with different mutation types of EGFR
Author(s):
ZHU Jinxiu; XIE Qiang; LE Yuyin; ZHONG Aihong
Department of Oncology,Fuzhou Pulmonary Hospital,Fujian Fuzhou 350008,China.
Keywords:
icotinib; lung adenocarcinoma; epidermal growth factor (EGFR); exon 19 deletion; exon 21 mutation
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2021.06.011
Abstract:
Objective:To analyse whether there is a difference between the efficacy of first-line treatment of icotinib in patients with different types of EGFR mutations lung adenocarcinoma.Methods:We collected 79 patients with advanced EGFR mutation lung adenocarcinoma in Fuzhou Pulmonary Hospital between January 2016 to December 2017.Among them,there were 33 cases of exon 19 deletion and 46 cases of exon 21 mutation.They all were treated with "icotinib 125 mg tid" orally and followed up for survival.χ2 test was used to compare clinical features and clinical efficacy between the two groups.Kaplan-Meier and Log-Rank methods were used to compare survival curves.Results:There was no difference in the clinical characteristics of patients between exon 19 group and 21 group in gender,age,smoking,brain metastasis,TNM stage,and pathological differentiation（P＞0.05）.There was no statistical difference in ORR (75.8% vs 71.7%) and DCR (97% vs 93.5%) between exon group 19 and 21 exon group (P＞0.05).The difference of median PFS (14.5 months vs 11 months) between EGFR 19 exon group and 21 exon variant group was statistically significant (χ2=4.112,P=0.043).The difference of median OS (26 months vs 17 months) between EGFR 19 exon group and 21 exon variant group was statistically significant (χ2=6.650，P=0.010).Conclusion:Advanced lung adenocarcinoma 19 exon deletion than 21 exon mutation after TKI treatment has survival advantage.

References:

［1］KOSAKA T,YALABE Y,ENDOH H,et al．MutaIions of the epideal growth factor recepcor gene in lung cancer:Biological and clinical implications［J］.Cancer Res，2004，64(24):8919-8923.
［2］YANG JC,WU Y,SCHULER M,et al.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma(LUX-Lung 3 and LUX-Lung 6)：analysis of overall survival data,from two randomised，phase 3 trials［J］.Lancet Oncology,2015,16(2):141-151.
［3］SHIGEMATSU H,LIN L,TAKAHSHI T,et al.Clinical and biological features associcated with epidermal growth factor receptor gene mutations in lung cancers［J］.J Natl Cancer Inst,2005,97(5):339-346.
［4］王艳,张申众,袁秀敏,等.EGFR基因19或21外显子突变非小细胞肺癌的临床病理特征及靶向治疗效果［J］.实用癌症杂志,2019,34(5):759-762. WANG Y,ZHANG SZ,YUAN XM,et al.Targeted therapy and clinicopathological features of patients with non-small cell lung cancer and Exon19 and 21 mutations in EGFR gene［J］.The Practical Journal of Cancer,2019,34(5):759-762.
［5］张庆丽,张筠,伍爱荣,等.厄洛替尼对EGFR基因不同突变型NSCLC患者疗效及生存率影响［J］.承德医学院学报,2019,36(3):202-204. ZHANG QL,ZHANG J,WU AR,et al.Effects of erlotinib on curative effects and survival rate of NSCLC patients［J］.Journal of Chengde Medical College,2019,36(3):202-204.
［6］李研,王艳梅,陈旭,等.晚期非小细胞肺癌表皮生长因子受体敏感突变类型与表皮细胞生长因子受体酪氨酸激酶抑制剂疗效的回顾性研究［J］.中华肺部疾病杂志（电子版）,2016,9(2):135-139. LI Y,WANG YM,CHEN X,et al.Retrospective study on epidermal growth factor receptor-tyrosine kinase inhibitor treatment in advanced non-small cell lung cancer patients harboring different epidermal growth factor receptor sensitive mutation sites［J］.Chin J Lung Dis(Electronic Edition),2016,9(2):135-139.
［7］WANG H,HUANG J,YU X,et al.Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer：a meta-analysis［J］.Journal of Cancer Research and Clinical Oncology,2014,140(11):1901-1909.
［8］黄诚,林根,雷源源.EGFR 19 Del的晚期非小细胞肺癌患者一线服用EGFR-TKIs的无进展生存期长于EGFR L858R患者［J］.循证医学,2015,15(1):25-28. HUANG C,LIN G,LEI YY.Patients with Exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer［J］.The Journal of Evidence-Based Medicine,2015,15(1):25-28.
［9］柯张延,张志红,张妍蓓,等.非小细胞肺癌EGFR基因不同突变位点对TKI治疗反应的meta分析［J］.安徽医科大学学报,2019,54(7):1101-1108. KE ZY,ZHANG ZH,ZHANG YP,et al.Meta-analysis of responses to TKI in different EGFR gene mutation sites with non-small cell lung cancer［J］.Acta Universitatis Medicinalis Anhui,2019,54(7):1101-1108.
［10］RAMALINGGAM SS,VANSTEENKISTE J,PLANCHARD D,et al.Overrall survival with osimertinibin untreated EGFR-mutated advanced NSCLC［J］.N Engl J Med,2020,82(3):41-50.
［11］洪卫卫,周云峰.19-del和21-L858 R突变非小细胞肺癌患者临床特点和疗效的差异［J］.医学新知,2018,28(2):182-185. HONG WW,ZHOU YF.Differences in clinical characteristics and efficacy of patients between 19-del and 21-L858 R mutation non-small cell lung cancer［J］.Journal of New Medicine，2018,28(2):182-185.
［12］ZHAO Y,LIU JT,CAI XY,et al.Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated non-small cell lung cancer:systematic review and network meta-analysis［J］.British Medical Journal，2019，367：15460.
［13］SAITO H.Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer(NEJ026):interim analysis of an open-label,randomized,multicentre,phase 3 trial［J］.Lancet Oncol，2019,20(5):625-635.
［14］ZHOU Q.ARTEMIS(CTONG1509):Phase 3 study of Bevacizumab with or without Erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC［J］.Annals of Oncology,2019,30(Supplement 5):v603.
［15］韦文娥,利基林,宁淑芳,等.EGFR 19-del和L858R突变型NSCLC患者预后比较［J］.山东医药,2016,56(17):22-25. WEI WE,LI JL,NING SF,et al.Comparison of prognosis of patients with EGFR 19-del and L858R mutant NSCLC［J］.Shandong Medical Journal，2016,56(17):22-25.
［16］董燕,贾莉,杨先锋.埃克替尼治疗不同外显子突变非小细胞肺癌的效果［J］.中国临床实用医学,2018,9(3):60-62. DONG Y,JIA L,YANG XF.Effect of icotinib on non-small cell lung cancer with different exon mutations［J］.China Clin Pract Med,2018,9(3):60-62.

Memo

Memo:
福州市临床医学中心资助项目（编号：2018080305）
Last Update: 1900-01-01